HUDDINGE, Sweden, Feb. 17, 2004 (PRIMEZONE) --
-- MIV-310 was outlicensed to Boehringer Ingelheim in July in a global licensing agreement with a total contract value of Eur 122 m.
-- MIV-210 was outlicensed in May to GlaxoSmithKline as part of a global licensing agreement with a total contract value of Eur 86 m of which Medivir received Eur 6 m at the time of signing the agreement.
-- In November, Roche and Medivir entered into two agreements within the field of virology. Within the HIV field, the companies restructured the existing collaborative agreement for MV026048 and, for hepatitis C, they entered into a new research partnership agreement.
-- In November, Medivir and Hengrui signed a research partnership agreement to develop drugs to combat chronic obstructive pulmonary disease (COPD).
-- In July, Medivir entered into a licensing agreement for MIV-150 with the Population Council.
-- In November, Medivir and Peptimmune Inc. were granted an EU patent for the use of Cathepsin S-inhibitor in therapeutic formulations for alleviating immune reactions.
-- Major progress has been made in the Cathepsin projects.
-- On 1 July, Medivir divested its subsidiary CCS for SEK 210 m.
-- Lars Adlersson entered the position as CEO and President on 1 March.
-- Net sales amounted to SEK 149.0 m inclusive CCS half-year (256.3 m inclusive CCS whole-year). Profit after tax were SEK -40.3 m (SEK -59.8 m), earnings per share amounted to SEK -4.69 (SEK -7.09).
FOR FURTHER INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP IR, +46 (0)8 5468 3123 or +46 (0)708 537292
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/02/17/20040217BIT00470/wkr0001.doc
The full report
http://www.waymaker.net/bitonline/2004/02/17/20040217BIT00470/wkr0002.pdf
The full report